After years of testing and development, a relatively small medical technologies developer has unveiled its long-awaited, pre-commercial prototype of a revolutionary new 3D breast imaging technology.
This completed prototype comes after four successive, fully-functioning breast CT prototypes were developed at UC Davis Medical Center as an academic pursuit. Commercialization efforts began when this company was granted the exclusive global licensing rights to the technology from The Regents of The University of California.
The device could be a game-changer for women’s health — potentially improving the lives of thousands of women every year.
The breakthrough breast imaging platform could allow radiologists to view high-resolution 3D images comparable to MRI as part of the initial, low-cost, low radiation dose routine breast cancer imaging in the future – as many as 40 million per year – and not have to order and then wait for expensive follow-up tests.
The “buzz” surrounding this new technology is real. The new device will be featured on an upcoming segment of the national TV show “Advancements with Ted Danson” via Amazon Prime Video and Bloomberg TV.1
A New, More Comfortable, More Private Method for Breast Imaging
A traditional diagnostic x-ray mammogram can require up to 12 individual “views,” with each view taking up to 20 seconds of painful, sometimes agonizing compression to complete.
Between each view, a technician has to handle the patient’s breast as it is repositioned in the compression plates. As a result, an x-ray mammogram can take between 20 and 45 minutes to complete.
What’s more, the images produced are often not ideal. Anatomical structures can be distorted, and there is no differentiation between macro-and micro-calcifications in the breast tissue – crucial for identifying potential tumors.
This device is radically different. Instead of women standing in front of an old-fashioned x-ray machine that requires vice-like breast compression between metal plates, the device lets women lie on a comfortable tabletop and place their own breast in an opening in the table.
Beneath the bed-like table, an advanced computed tomography (CT) camera moves around the breast in a 360-degree circle, taking approximately 500 images in just 10 seconds.
Proprietary AI computer software then takes these 500 raw image slices of the non-compressed breast and reconstructs the slices into high-resolution 3D images of the entire breast.
The pre-commercialized prototypes created at UC Davis have been used in extensive academic clinical trials with more than 600 patients. UC Davis is currently in the data analysis stage of a clinical trial comparing breast CT to MRI, with the results to be released soon.
The Advantages of High-Resolution 3D Imaging Over Traditional Mammograms
The greater comfort and privacy are of paramount importance, but they are merely two of the many benefits of CT imaging for breast diagnostics.
First, this breakthrough 3D imaging system eliminates compression altogether.
Natural breast orientation is preserved with the patient placing her own breast in the imaging cup, so there is no embarrassing handling by a technician. This also ensures that there is excellent visualization with contrast.
Further, the imaging procedure is over in a flash. The system takes 500 high-resolution images in approximately 10 seconds with about the same level of radiation from just two traditional mammogram views. What’s more, this company is developing new image reconstruction software utilizing the latest machine learning algorithms to deliver both high resolution and low noise images at low radiation dose levels.
Aside from improved detection capabilities this device is a potential solution for more precise margin analysis (viewing edges of a tumor), better “lesion characterization” (the detailed description of an abnormality), and higher spatial resolution, allowing radiologists to better differentiate internal breast structures.
Women and Doctors Eager for the “Next Stage” in Breast Health
As a result, the “buzz” is substantial around this potentially breakthrough technology in women’s health – and it’s not just investors that are so excited about the 3D imaging platform.
Patients are already asking when the technology will be available and for a good reason!
Half of Women Will Likely Get a Devastating False Breast Cancer Diagnosis
False positives are common in traditional breast imaging: False positives are when old-fashioned mammograms reveal abnormalities in the breast tissue that later tests and biopsies reveal are actually benign and not cancerous tumors.
About 50 percent of women who get annual mammograms over a ten-year period will have a false-positive finding at least once.
The problem is, these false positives cause tremendous stress and worry for thousands of women, not to mention unnecessary biopsy procedures – and the follow-up imaging exams and biopsies can cost tens of thousands of dollars per patient.
The Market for Breast Imaging to Soar to $5.4 Billion by 2025
Thus, the market for this new breast imaging platform is potentially enormous. It’s estimated that the market for breast imaging technology will grow from $3.7 billion in 2020 to $5.4 billion by 2025.2
What’s more, 40 million women receive a mammogram each year in the United States.
Of these, about 10 percent – or 4 million — are called back for expensive follow-up tests, such as diagnostic mammograms, tomosynthesis, ultrasound, MRI, and biopsies.3
An advanced breast imaging technology like the one this company has designed and is submitting to the FDA could potentially save America’s struggling health care systems billions of dollars – and would be extremely attractive for hospitals and health care managers.
A recent study found that the cost of follow-up imaging and diagnostic procedures after initial mammograms was more than $8 billion4 annually, just in the United States alone.
Hundreds of Millions of Women Could Soon Demand This Technology
Women worldwide have already begun hearing about a brand-new, easy, and compression-free way to do breast imaging – lying comfortably for a few seconds on an imaging table rather than standing in front of an x-ray machine while their breasts are compressed between metal plates.
As word continues to get out, the demand for this disruptive new technology could be intense.
Enter your email address to learn more about this innovative new company now, before it submits this major breakthrough in breast imaging technology to the FDA.
1https://izocorp.com/news-releases/izotropics-izoview-breast-ct-device-to-be-featured-on-advancements-tv-show-in-usa/
2https://www.marketsandmarkets.com/PressReleases/breast-imaging-technologies.asp
3Corporate Presentation, September 2020, p. 10.
4Slide 7, https://izocorp.com/site/assets/files/5623/final_jan_2023_izo_investor_presentation.pdf
Legal Notice: This website is owned and hosted by Market Tactic Media Ltd. Articles appearing on this website should be considered paid advertisements. Market Tactic Media Ltd. and its owners, managers, employees, and assigns (collectively “the Website Host”) is often paid by marketing companies to host websites on which articles profiling public companies are published. The articles on this website are not, and should not be construed to be, offers to sell or solicitations of an offer to buy any security. Neither the articles on this website nor the Website Host purport to provide a complete analysis of any company or its financial position. The Website Host is not, and does not purport to be, a broker-dealer or registered investment adviser. The articles on this website are not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the profiled company’s SEC and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk.
